The effectiveness and safety of a drug-releasing balloon in active cancer patients presenting with ST-segment elevation myocardial infarction (heart attack)

Comparisons of a drug-eluting balloon versus drug-eluting stent for the treatment of active cancer patients presenting with ST-segment elevation myocardial infarction: a randomized clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN19138402

Enrollment

164

Registered

2022-09-27

Start date

2023-01-01

Completion date

Unknown

Last updated

2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optimal management of active cancer patients presenting with STEMI Circulatory System

Interventions

Eligible patients are randomly assigned at a 1:1 ratio to either DEB or DES according to a computer-generated randomization schedule, which is performed by an independent authorized researcher, who is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 80 years 2. First STEMI attack 3. Presenting within 12 h of symptom onset 4. Active cancer

Exclusion criteria

Exclusion criteria: 1. Previous myocardial infarction 2. Non-ST-segment elevation myocardial infarction and unstable angina pectoris 3. Unconsciousness or cardiogenic shock 4. Symptom onset >12 h 5. Mechanical complications 6. Historical cancer

Design outcomes

Primary

Measure	Time frame
Major bleeding events measured using hospital records and telephone interviews at 6 months and 1 year	—

Secondary

Measure	Time frame
1. Thrombolysis in Myocardial Infarction (TIMI) grade measured using coronary angiography immediately post PCI 2. Resolution of ST-segment elevation (STR) measured using electrocardiogram at 60 min after PCI 3. Cardiac biomarkers level measured using enzyme-linked immunosorbent assay at 24 h, 48 h, and 72 h post PCI 4. Left ventricular ejection fraction (LVEF) measured using echocardiography within 3 days after PCI 5. Cardiac complications measured using hospital records during hospitalization 6. Major adverse cardiac event (MACE) measured using hospital records as well as by telephone interviews during 1-year clinical follow-up	—

Measure

Time frame

1. Thrombolysis in Myocardial Infarction (TIMI) grade measured using coronary angiography immediately post PCI 2. Resolution of ST-segment elevation (STR) measured using electrocardiogram at 60 min after PCI 3. Cardiac biomarkers level measured using enzyme-linked immunosorbent assay at 24 h, 48 h, and 72 h post PCI 4. Left ventricular ejection fraction (LVEF) measured using echocardiography within 3 days after PCI 5. Cardiac complications measured using hospital records during hospitalization 6. Major adverse cardiac event (MACE) measured using hospital records as well as by telephone interviews during 1-year clinical follow-up

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026